MIT Technology Review Subscribe

Diabetes treatment without injections

An implantable device contains encapsulated cells that produce insulin, plus a tiny oxygen-producing factory that keeps them healthy.

MIT engineers have come one step closer to the goal of treating diabetes without frequent insulin shots.

In type 1 diabetes, the body is unable to produce the insulin required to regulate blood sugar, so people must carefully monitor their glucose levels and inject insulin as needed. Implanting replacements for the pancreatic islet cells that normally produce insulin is a potentially simpler and more effective approach, but there are obstacles. One is that whether they are derived from human cadavers or stem cells, the transplanted cells can be rejected by the immune system, so patients need to take immunosuppressive drugs. Encapsulating the transplanted cells in a flexible device can solve that problem, but the cells in such devices eventually run out of oxygen and stop producing insulin. And finding a reliable oxygen supply has proved challenging.

Advertisement

The MIT team approached the problem by developing an implant that not only carries hundreds of thousands of insulin-producing islet cells but also has its own onboard oxygen factory. When implanted into diabetic mice, a device about the size of a US quarter kept their blood glucose stable for at least a month. The researchers now hope to create a larger version, about the size of a stick of chewing gum, that could eventually be tested in people.

This story is only available to subscribers.

Don’t settle for half the story.
Get paywall-free access to technology news for the here and now.

Subscribe now Already a subscriber? Sign in
You’ve read all your free stories.

MIT Technology Review provides an intelligent and independent filter for the flood of information about technology.

Subscribe now Already a subscriber? Sign in

“You can think of this as a living medical device that is made from human cells that secrete insulin, along with an electronic life-support system,” says chemical engineering professor Daniel Anderson, a member of MIT’s Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science (IMES), who is the senior author of a study on the work. 

To generate the oxygen, the MIT researchers used a proton-exchange membrane, a technology originally deployed to generate hydrogen in fuel cells. This membrane can split water vapor (found abundantly in the body) into hydrogen, which diffuses harmlessly away, and oxygen, which goes into a storage chamber that feeds the islet cells.

A significant advantage of this approach is that it does not require any wires or batteries. Splitting the water vapor requires only about two volts, generated using a phenomenon known as resonant inductive coupling: a tuned magnetic coil located outside the body transmits power to a small, flexible antenna within the device. It does require an external coil, which the researchers expect could be worn as a skin patch.

While the researchers’ main focus is on diabetes, they say this kind of device could also be adapted to treat other diseases that require repeated delivery of therapeutic proteins. Their study showed that it could sustain not just islet cells but also cells that produce erythropoietin, a protein that stimulates production of red blood cells.

“We’re optimistic that it will be possible to make living medical devices that can reside in the body and produce drugs as needed,” Anderson says. “If we can replace the need for infusions every other week with a single implant that can act for a long time, I think that could really help a lot of patients.” 

This is your last free story.
Sign in Subscribe now

Your daily newsletter about what’s up in emerging technology from MIT Technology Review.

Please, enter a valid email.
Privacy Policy
Submitting...
There was an error submitting the request.
Thanks for signing up!

Our most popular stories

Advertisement